Cancer Research and Treatment

Original Articles

Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy: Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, In Gyu Hwang, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, In Sook Woo, Soojung Hong, Tae-Yong Kim, Ji Yeon Baek, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Hun-Mo Ryoo, Kyung Hee Lee, Jee Hyun Kim; Cancer Res Treat. 2019;51(3):1249-1256. Published online January 2, 2019; DOI: https://doi.org/10.4143/crt.2018.451

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to prospectively validate the Korean Cancer Study Group Geriatric Score (KG)-7, a novel geriatric screening tool, in older patients with advanced cancer planned to undergo first-line palliative chemotherapy.
Materials and Methods
Participants answered the KG-7 questionnaire before undergoing geriatric assessment (GA) and first-line palliative chemotherapy. The performance of KG-7 was evaluated by calculating the sensitivity (SE), specificity (SP), positive and negative predictive value (PPV and NPV), balanced accuracy (BA), and area under the curve (AUC).
Results
The baseline GA and KG-7 results were collected from 301 patients. The median age was 75 years (range, 70 to 93 years). Abnormal GA was documented in 222 patients (73.8%). Based on the ≤ 5 cut-off value of KG-7 for abnormal GA, abnormal KG-7 score was shown in 200 patients (66.4%). KG-7 showed SE, SP, PPV, NPV, and BA of 75.7%, 59.7%, 84.4%, 46.0%, and 67.7%, respectively; AUC was 0.745 (95% confidence interval, 0.687 to 0.803). Furthermore, patients with higher KG-7 scores showed significantly longer survival (p=0.006).
Conclusion
KG-7 appears to be adequate in identifying patients with abnormal GA prospectively. Hence, KG-7 can be a useful screening tool for Asian countries with limited resources and high patient volume.

Citations

Citations to this article as recorded by

Comparison of two frailty screening tools in older patients with colorectal cancer
Han Zhao, Xinlin Lu, Senshuang Zheng, Danmei Wei, Lizhong Zhao, Yuan Wang, Geertruida H. de Bock, Wenli Lu
BMC Geriatrics.2023;[Epub] CrossRef
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong, Tae-Yong Kim, Sun Young Kim, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Kyung Hee Lee,
Cancers.2021; 13(2): 331. CrossRef
A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
Journal of Geriatric Oncology.2021; 12(6): 922. CrossRef
Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)
Helena Møgelbjerg Ditzel, Ann-Kristine Weber Giger, Cecilia Margareta Lund, Henrik Jørn Ditzel, Afsaneh Mohammadnejad, Per Pfeiffer, Jesper Ryg, Trine Lembrecht Jørgensen, Marianne Ewertz
Journal of Geriatric Oncology.2021; 12(8): 1270. CrossRef
The Globalization of Geriatric Oncology: From Data to Practice
Ravindran Kanesvaran, Supriya Mohile, Enrique Soto-Perez-de-Celis, Harpreet Singh
American Society of Clinical Oncology Educational Book.2020; (40): e107. CrossRef

9,722 View
180 Download
4 Web of Science
5 Crossref

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis: Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung-Chul Mun, Young Rok Do, Hun-Mo Ryoo, Je-Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh; Cancer Res Treat. 2015;47(2):173-181. Published online October 28, 2014; DOI: https://doi.org/10.4143/crt.2014.055

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients’ case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Citations

Citations to this article as recorded by

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
Xiaoxuan Lu, Yu Liu, Ruyu Liu, Jiaxin Liu, Xiaojing Yan, Liren Qian
Frontiers in Oncology.2022;[Epub] CrossRef
Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia
Cancer Medicine.2019; 8(3): 874. CrossRef
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines
Jun Liu, Junshik Hong, Kwang-Sung Ahn, Junhyeok Go, Heejoo Han, Jihyun Park, Dongchan Kim, Hyejoo Park, Youngil Koh, Dong-Yeop Shin, Sung-Soo Yoon
Leukemia & Lymphoma.2019; 60(10): 2532. CrossRef
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
International Journal of Hematology.2018; 107(4): 395. CrossRef
Recent advances in treating extra-ocular lymphomas
Lauge Hjorth Mikkelsen, Natacha Storm Würtz, Steffen Heegaard
Expert Review of Ophthalmology.2018; 13(4): 205. CrossRef
The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
Cheolwon Suh, Byeong-Bae Park, Won Seog Kim
Blood Research.2017; 52(1): 3. CrossRef
Primary lymphomas in the gastrointestinal tract
Jiang Chen Peng, Lu Zhong, Zhi Hua Ran
Journal of Digestive Diseases.2015; 16(4): 169. CrossRef

16,063 View
145 Download
10 Web of Science
7 Crossref

Case Report

Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation: Hye Ryun Jung, So Yeon Yun, Jun Hyeok Choi, Sung Hwa Bae, Hun-Mo Ryoo, Yoon-Seup Kum; Cancer Res Treat. 2011;43(4):255-259. Published online December 27, 2011; DOI: https://doi.org/10.4143/crt.2011.43.4.255

Abstract PDF PubReader ePub

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare T-cell lymphoma characterized by involvement of the subcutaneous tissue of neoplastic T lymphocytes. SPTCL with hemophagocytic syndrome (HPS) is associated with an aggressive clinical course and treatment of SPTCL with HPS is not well established. Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy is not successful in most patients suffering from SPTCL with HPS. The role of high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT) remains controversial. We report a case of relapsed SPTCL after CHOP chemotherapy and salvage chemotherapy followed by autologous HSCT, which had rapid improvement within weeks after cyclosporine and prednisolone. Immunosuppressive therapy may be an important and successful treatment option in SPTCL patients, even though they may have clinically aggressive disease.

Citations

Citations to this article as recorded by

Rare Cutaneous T-Cell Lymphomas
Fabiana Damasco, Oleg E. Akilov
Hematology/Oncology Clinics of North America.2019; 33(1): 135. CrossRef
Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population
Ting-An Lin, Ching-Fen Yang, Yao-Chung Liu, Jin-Hwang Liu, Tzeon-jye Chiou, Liang-Tsai Hsiao, Hsiu-Ju Yen, Chia-Jen Liu, Hao-Yuan Wang, Po-Shen Ko, Sheng-Hsuan Chien, Jyh-Pyng Gau
International Journal of Hematology.2019; 109(2): 187. CrossRef
A Systematic Approach to the Cutaneous Lymphoid Infiltrates: A Clinical, Morphologic, and Immunophenotypic Evaluation
Alejandro A. Gru, Chauncey McHargue, Andrea L. Salavaggione
Archives of Pathology & Laboratory Medicine.2019; 143(8): 958. CrossRef
Subcutaneous panniculitis-like T-Cell lymphoma: A mixed diagnostic approach to diagnosing a vague clinical picture
Callie Roberts Hill, Apphia Wang, Boni E. Elewski, Peter G Pavlidakey
SKIN The Journal of Cutaneous Medicine.2019; 3(2): 90. CrossRef
Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients
Ingrid López-Lerma, Yeray Peñate, Fernando Gallardo, Rosa M. Martí, Josune Mitxelena, Isabel Bielsa, Virginia Velasco-Tamariz, Juan I. Yanguas-Bayona, Pedro Sánchez-Sambucety, Vicente García-Patos, Pablo L. Ortiz-Romero, Ramón M. Pujol, Teresa Estrach
Journal of the American Academy of Dermatology.2018; 79(5): 892. CrossRef
Uncommon Variants of T-Cell Lymphomas
Neha Mehta-Shah, Steven Horwitz
Hematology/Oncology Clinics of North America.2017; 31(2): 285. CrossRef
Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review
Chi-Ching Chen, Chieh-Lin Teng, Su-Peng Yeh
Annals of Hematology.2016; 95(5): 837. CrossRef
Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides
Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, Patricia L. Myskowski, Alison Moskowitz, Steven M. Horwitz
Current Hematologic Malignancy Reports.2016; 11(3): 224. CrossRef
Zebras and hen's teeth: recognition and management of rare T and NK lymphomas
Neha Mehta–Shah, Steven Horwitz
Hematology.2015; 2015(1): 545. CrossRef
Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission
Won Sup Lee, Ji-Hyen Hwang, Moon Jin Kim, Se-Il Go, Anna Lee, Haa-Na Song, Min Jeong Lee, Myung Hee Kang, Hoon-Gu Kim, Jeong-Hee Lee
Cancer Research and Treatment.2014; 46(3): 312. CrossRef

10,481 View
93 Download
10 Crossref

Original Article

The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy: Sang-Joon Shin, Min-Kyoung Kim, Kyung-Hee Lee, Myung-Soo Hyun, Sang Woon Kim, Sun Kyo Song, Sung-Hwa Bae, Hun-Mo Ryoo; Cancer Res Treat. 2004;36(6):367-371. Published online December 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.6.367

Abstract PDF PubReader ePub

Purpose

This study was conducted to confirm the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy (DP) in patients with advanced gastric cancer.

Materials and Methods

Patients with measurable gastric adenocarcinoma received intravenous docetaxel 75 mg/m² and cisplatin 75 mg/m² with premedication on day 1, which was repeated every 3 weeks. All patients received DP as a second-line treatment after failing to 5-FU based chemotherapy.

Results

34 patients were enrolled in this study between January 1998 and August 2003. A total of 112 cycles (median 3 cycles) were administered. Responses were evaluable in 30 patients. The objective response rate was 16.7% (95% CI: 3.5~30.3), with a stable disease in 56.7% (95% CI: 40.0~74.4) and a progressive disease in 26.7% (95% CI: 10.9~42.5) of patients, with a median follow up duration of 20 months for all the patients, The median duration of response, time to progression and overall survival were 2.1 months (95% CI: 0.4~3.9), 4.2 months (95% CI: 2.3~6.1) and 6.8 months (95% CI: 1.3~12.3), respectively, with a 1-year survival rate of 32%. The toxicity was evaluated in 30 patients, with neutropenia being most common. Renal impairment was seen in two patients with grade 3 creatinine elevation and liver enzyme elevation in four with grades 3 and 4.

Conclusion

Although DP was an active combination regimen, with a tumor control rate of about 73% and with moderate tolerance, adjustment of the administration schedule, with further evaluation of other combination chemotherapies of docetaxel with new agents, other than cisplatin, seem warranted.

Citations

Citations to this article as recorded by

Neoadjuvant chemotherapy for gastric cancer: A meta‐analysis of randomized, controlled trials
Yi Liao, Zu‐li Yang, Jun‐sheng Peng, Jun Xiang, Jian‐ping Wang
Journal of Gastroenterology and Hepatology.2013; 28(5): 777. CrossRef
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Hyun Cheol Chung
Cancer Chemotherapy and Pharmacology.2007; 61(1): 157. CrossRef
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
Seung Tai Kim, Joon Oh Park, Jeeyun Lee, Kyu Taek Lee, Jong Kyun Lee, Seong-Ho Choi, Jin-Seok Heo, Young Suk Park, Won Ki Kang, Keunchil Park
Cancer.2006; 106(6): 1339. CrossRef
Isolated tumor cells in lymph nodes are not a prognostic marker for patients with stage I and stage II colorectal cancer
Min Ro Lee, Chang Won Hong, Sang Nam Yoon, Seok-Byung Lim, Kyu Joo Park, Min Jin Lee, Woo Ho Kim, Jae-Gahb Park
Journal of Surgical Oncology.2006; 93(1): 13. CrossRef
Radical Radiotherapy for Locally Advanced Cancer of Uterine Cervix
Jeung Eun Lee, Seung Jae Huh, Won Park, Do Hoon Lim, Yong Chan Ahn, Chang Soo Park, Byoung Gie Kim, Duk Soo Bae, Je Ho Lee, Chong Taik Park, Tae Jin Kim, Kyung Taek Lim, Hwan Wook Chung, Ki Heon Lee, Jae Uk Shim
Cancer Research and Treatment.2004; 36(4): 222. CrossRef

8,170 View
46 Download
5 Crossref

First
Prev
Page of 1
Next
Last

Search